Seremet, TeofilaTeofilaSeremetDi Domizio, JeremyJeremyDi DomizioGirardin, AntoineAntoineGirardinYatim, AhmadAhmadYatimJenelten, RaphaelRaphaelJeneltenMessina, FrancescoFrancescoMessinaSaidoune, FannyFannySaidouneSchlapbach, ChristophChristophSchlapbachBogiatzi, SofiaSofiaBogiatziMinisini, FredericFredericMinisiniGarzorz-Stark, NatalieNatalieGarzorz-StarkLeuenberger, MatthieuMatthieuLeuenbergerWüthrich, HéloiseHéloiseWüthrichVernez, MaximeMaximeVernezHohl, DanielDanielHohlEyerich, StefanieStefanieEyerichEyerich, KilianKilianEyerichGuenova, EmmanuellaEmmanuellaGuenovaPaul, CarleCarlePaulGottardo, RaphaelRaphaelGottardoConrad, CurdinCurdinConradGilliet, MichelMichelGilliet2025-01-162025-01-162024-12-18https://boris-portal.unibe.ch/handle/20.500.12422/194684Previous advances have identified immune pathways associated with inflammatory skin diseases, leading to the development of targeted therapies. However, there is a lack of molecular approaches that delineate these pathways at the individual patient level for personalized diagnostic and therapeutic guidance. Here, we conduct a cross-comparison of expression profiles from multiple inflammatory skin diseases to identify gene modules defining relevant immune pathways. Seven modules are identified, representing key immune pathways: Th17, Th2, Th1, Type I IFNs, neutrophilic, macrophagic, and eosinophilic. These modules allow the development of a molecular map with high diagnostic efficacy for inflammatory skin diseases and clinico-pathologically undetermined cases. Aligning dominant modules with treatment targets offers a rational framework for treatment selection, improving response rates in both treatment-naïve patients and non-responders to targeted therapies. Overall, our approach offers precision medicine for inflammatory skin diseases, utilizing transcriptional modules to support diagnosis and guide personalized treatment selection.en600 - Technology::610 - Medicine & healtharticle10.48620/847033969516210.1038/s41467-024-54559-6